Next Article in Journal
Challenges in Tick-Borne Pathogen Detection: The Case for Babesia spp. Identification in the Tick Vector
Next Article in Special Issue
Occurrence and Characteristics of Staphylococcus aureus in a Hungarian Dairy Farm during a Control Program
Previous Article in Journal
Subtype Characterization and Zoonotic Potential of Cryptosporidium felis in Cats in Guangdong and Shanghai, China
Previous Article in Special Issue
Enterotoxigenic Potential of Coagulase-Negative Staphylococci from Ready-to-Eat Food
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Novel Treatments and Preventative Strategies Against Food-Poisoning Caused by Staphylococcal Species

1
Departamento de Biología Molecular, Área de Microbiología, Universidad de León, 24071 León, Spain
2
Instituto de Biología Molecular, Genómica y Proteómica (INBIOMIC), Universidad de León, 24071 León, Spain
3
Instituto de Desarrollo Ganadero y Sanidad Animal (INDEGSAL), Universidad de León, 24071 León, Spain
*
Authors to whom correspondence should be addressed.
Pathogens 2021, 10(2), 91; https://doi.org/10.3390/pathogens10020091
Submission received: 31 December 2020 / Revised: 14 January 2021 / Accepted: 16 January 2021 / Published: 20 January 2021

Abstract

:
Staphylococcal infections are a widespread cause of disease in humans. In particular, S. aureus is a major causative agent of infection in clinical medicine. In addition, these bacteria can produce a high number of staphylococcal enterotoxins (SE) that may cause food intoxications. Apart from S. aureus, many coagulase-negative Staphylococcus spp. could be the source of food contamination. Thus, there is an active research work focused on developing novel preventative interventions based on food supplements to reduce the impact of staphylococcal food poisoning. Interestingly, many plant-derived compounds, such as polyphenols, flavonoids, or terpenoids, show significant antimicrobial activity against staphylococci, and therefore these compounds could be crucial to reduce the incidence of food intoxication in humans. Here, we reviewed the most promising strategies developed to prevent staphylococcal food poisoning.

1. Introduction

The bacteria belonging to the genus Staphylococcus are generally classified as coagulase-positive or coagulase-negative species. Among all of them, Staphylococcus aureus is the leading cause of human disease. Moreover, staphylococcal food poisoning (SFP) is a common disease, and the number of cases had increased continuously since 1884 when the first case was reported to become one of the most common causes of foodborne disease [1]. In addition, coagulase-negative staphylococci and their toxins could also be an important source of food contamination, particularly in ready-to-eat products, milk, cheese, milk chocolate, or canned meat [2,3,4,5,6,7,8,9]. This may lead to food intoxication due to the presence of staphylococcal exotoxins, which were firstly identified in 1992 [7]. Moreover, the inappropriate manipulation of fresh food may lead to outbreaks originated in restaurants because S. aureus could also be transmitted from human carriers during food handling [10,11]. Furthermore, food production animals, including pigs, cattle, or chickens, may also be carriers of S. aureus [1]. In fact, the use of antibiotics in animal production has increased the incidence of livestock-associated antibiotic-resistant strains [1,12,13].
The existence of a robust and straightforward PCR test that detects microorganisms with genes that encode exotoxins has allowed the detection of hundreds of staphylococcal food-poisoning outbreaks every year [14]. However, a high exotoxin production is not directly correlated with a higher disease incidence. Therefore, other alternative analytical methods have been routinely employed to identify the presence of exotoxins in food, including those based on high-performance liquid chromatography (HPLC) and mass spectrometry (MS) [15]. Unfortunately, there is a wide range of exotoxins produced by pathogens from the staphylococcal group, making it challenging to identify the origin of the food intoxication [6].
Moreover, the pasteurization of food destroys staphylococci, but it usually does not affect exotoxins’ activity, which may still cause disease in humans after food processing [6]. Besides, some S. aureus strains can resist high concentrations of lactic acid, which facilitates their growth in various foods, including cheese, meat, salads, or milk chocolate [1,9,15,16].
In addition, coagulase-negative staphylococci in food are important reservoirs of antimicrobial resistance genes, virulence factors, and exotoxins [3,17,18]. This is now considered a significant health problem because these genes could be horizontally transmitted to coagulase-positive staphylococci, which may increase the incidence of foodborne disease [17,19,20,21].
In summary, there is a great interest in developing novel ways of preventing the presence of Staphylococcus spp. and their exotoxins in food to reduce the incidence of intoxications. Natural compounds used as food supplements are now considered an up-and-coming strategy to decrease the staphylococcal colonization of food.

2. Staphylococcal Enterotoxins and Virulence Factors

Staphylococcus spp. exotoxins present in food are a group of low-molecular-weight pyrogenic proteins of around 22–29 kDa, with important similarities in their secondary and tertiary structures [1,17,22,23,24]. These exotoxins are grouped into three different families depending on their aminoacidic sequence: Staphylococcal enterotoxins (SE), Staphylococcal enterotoxin-like (SEl), and the toxic shock syndrome toxin 1 (TSST-1) [1]. Other toxins related to TSST-1 but showing a different mechanism of action have now been classified as staphylococcal superantigen-like (SSl) [24].
Different species of Staphylococcus can produce exotoxins, including coagulase-negative strains that are considered non-pathogenic. However, picomolar concentrations of SEs can cause toxic shock syndrome (TSS), fever, hypotension, and multi-organ failure that enhance the disease caused by S. aureus [25,26]. In addition, the SE and TSST-1 are also considered superantigens (SAgs) because they have the potential to activate T cells through a complex signaling pathway and stimulate a hyper-inflammatory response [24,27]. SAgs are implicated in the development of sepsis, infective endocarditis, and other complications [28].
Among all staphylococcal toxins, SEs have been the most frequently associated with foodborne diseases, causing emesis and T-cell activation [29]. There are at least 26 different SEs characterized, but this number could be even higher [10]. These toxins are resistant to heat and acidity and to the hydrolysis mediated by most proteolytic enzymes [1,17].
While SEs and TSST-1 directly activate macrophages and T-cells, SEl and SSl are considered capable of general immunomodulation [24]. However, SEl proteins can induce neither emesis nor T-cell activation [27]. Moreover, some staphylococcal toxins show a proapoptotic activity essential for S. aureus colonization [27]. SEs may cause cytotoxicity in intestinal cells, which results in gastroenteritis, vomiting, and gastric inflammation [29].
Despite that coagulase-negative strains could be involved in food-poisoning and may even release toxins that cause the lethal toxic shock syndrome [4,22,30], S. aureus is still considered the leading cause of staphylococcal gastroenteritis and food intoxication [7,9]. There are important outbreaks caused periodically by S. aureus and its toxins, and in most cases, the staphylococcal enterotoxin A (SEA) is involved [5,7].
In addition, other virulence factors encoded in the genome of different staphylococcal strains could be putative sources of gastrointestinal diseases. In fact, several virulence factors are essential for the successful colonization of the host, including coagulase, staphylokinase, adhesins, protein A, and β-hemolysin [31,32,33]. Their expression is under the control of several regulatory genes and sometimes under the control of noncoding RNAs. The expression of this plethora of virulence factors is indirectly regulated by pH, temperature, and other changing conditions that the pathogen encounters in food or during infection [31,34].
Finally, discovering the toxin-antitoxin (TA) system has revolutionized the search for novel therapies against staphylococci [35]. The TA system is composed mainly of two genes encoding an antitoxin (usually located upstream of an operon) and the toxin (located downstream). The first gene is self-regulated, and both the antitoxin and the toxin-antitoxin complex may repress the TA operon’s promoter [36,37]. During infection, the host proteases degrade the antitoxin protein, enabling the expression of the toxin [36]. There is much interest in developing treatments that may inhibit the antitoxin protein’s degradation or even block the antitoxin-toxin interactions, which could be a natural and broad-spectrum antibacterial treatment [36,37].

3. Treatments Against Staphylococcal Food Poisoning

Traditionally, the treatments against staphylococcal food-poisoning are focused on either controlling exotoxins or the control of the transmission of the bacteria. The use of antimicrobials to treat staphylococcal food intoxications is not recommended due to the additional release of staphylococcal toxins after bacterial cell death, leading to septic shock. Besides, if antibiotic therapy is administered to patients infected by multidrug-resistant staphylococci, this could facilitate colonization of the gastrointestinal tract once the sensitive intestinal flora is altered. Consequently, antimicrobial-resistant staphylococci may then replicate and secrete more toxins that could aggravate the disease [38].

3.1. Monoclonal Antibodies and Vaccines

S. aureus is a natural commensal of the human skin; however, it can circumvent the host immune system, and it is a facultative intracellular pathogen [39]. These two aspects of the pathogenesis of S. aureus are the main causes of the failure of all vaccine candidates tested in humans and based on opsonization [40,41,42]. However, the production of antibodies against staphylococcal extracellular proteins protect patients against sepsis caused by S. aureus [43]. Therefore, the development of monoclonal antibodies-based therapies against specific staphylococcal toxins is now considered a very promising strategy to generate protection against S. aureus [44]. Importantly, this strategy has been successfully tested in clinical trials against toxins from Clostridium difficile or Escherichia coli [35].
Monoclonal antibodies-based therapies are effective against many other bacteria [45,46], particularly against the most virulent species [46]. However, due to the high number of toxins produced by S. aureus, it is becoming clear that therapies based on monoclonal antibodies targeting a single toxin are frequently ineffective [25]. Therefore, there is interest in developing combinatorial therapies against multiple S. aureus enterotoxins and other virulence factors, including extracellular or cell-wall anchored proteins [42,45,47,48,49,50,51]. In particular, monoclonal antibodies-based therapies have been developed against multiple staphylococcal enterotoxins and TSST-1 [42,51,52]. Some of these therapies are undergoing clinical trials [45]. This type of therapy could also be used to prevent the spread of the disease in animals infected by livestock-associated multidrug-resistant strains [53]. However, the high cost of this type of treatment makes this strategy difficult to be implemented in animal production.
In addition, some studies have been focused on developing immunotherapies targeting the staphylococcal α-toxin [42]. This is based on recent evidence showing a high titter of anti-α-toxin antibodies protect against future infections. However, a vaccine developed against different variants of the α-toxin was not effective in humans, despite that it provided effective protection in mouse pneumonia models [54,55]. Nevertheless, these results support the development of multi-target immunotherapies.
Interestingly, TSST-1 is another important target for the development of immunotherapies. Similar to α-toxin, it has been demonstrated that antibodies generated against TSST-1 may protect patients against future infections [56,57]. Accordingly, 80% of the human population develops antibodies against TSST-1 during the first years of life [58]. A vaccine has been developed to provide immunity against TSST-1 in the remaining 20% of the population, which is also undergoing clinical trials [59,60].
Other interesting targets for immunotherapy-based strategies are virulence factors such as the iron-regulated surface determinants (Isd) proteins, which are located on the extracellular matrix of biofilms produced by S. aureus [61]. Moreover, the toxin-antitoxin system could be disrupted by monoclonal antibodies that bind to the toxin but not to the antitoxin [36].
Overall, monoclonal antibodies showed promising results in animal models, but data from clinical trials in humans are still not available or conclusive [48,61]. However, a cocktail of monoclonal antibodies protects mice from S. aureus infections very efficiently [48,61].

3.2. Natural Compounds Against Staphylococcal Infections

As mentioned above, a plethora of toxins, virulence factors, and antimicrobial resistance traits make S. aureus a principal cause of foodborne disease. In addition, the biofilm structures created by this pathogen increase its resistance to antimicrobials [62,63]. Fortunately, there is an increasing body of knowledge on natural compounds derived from plants or microorganisms that could be used as dietary supplements to prevent staphylococcal infections and the spreading of their antimicrobial resistance.
In general, the therapeutic strategies based on natural compounds could be classified by their mode of action in antimicrobial or anti-virulence therapies [64]. Antimicrobial therapies act directly on the bacteria to inhibit their growth, whereas anti-virulence therapies are based on inhibitors of bacterial virulence factors [65]. Importantly, anti-virulence therapies do not directly affect bacterial fitness, and therefore they elicit a limited evolutionary pressure that reduces the development of resistance [35].
Many natural compounds directly inhibit bacterial growth or replication. In particular, polyphenols are very well-known antimicrobial compounds present in significant concentrations in plants (Table 1). Importantly, the combination of polyphenols with other antimicrobial compounds may be synergistic [62], making them very attractive candidates for the development of combinatorial strategies used to prevent staphylococcal food contamination.
Some of these compounds repress SEs production, whereas others directly interact with enterotoxins and inhibit their mechanism of action. Some of the latter could be used as additives to inhibit SEs-derived food intoxication, particularly in products treated with sterilization or pasteurization processes where staphylococci may be killed. However, their already secreted exotoxins could still be active in contaminated food [1]. Therefore, enterotoxin-directed treatments can be used against S. aureus-contaminated and SEs-contaminated food [25], whereas treatments that alter the expression of the genes encoding enterotoxins expression are not effective once SEs are already present in food.
For example, the Muscadine grape’s skin is rich in gallic and ellagic acids, which show significant antimicrobial activity against S. aureus [62]. The crude extracts of other plant species such as Chenopodium album are rich in phenolic and flavonoid compounds with powerful antibacterial activity against S. aureus, equivalent to many antibiotics used in clinical medicine [66]. Aloe vera, black garlic, eucalyptus, or grape seeds could be the source of many other natural compounds with antimicrobial activity [64]. This is due to phenolic and phenolic-derivative compounds and alkaloids, fatty acids, organo-sulfurs, and other aliphatic and cyclic compounds that in total amount to hundreds of molecules with anti-staphylococcal activity [35,64].
In addition, some of these plant-derived compounds show activity against SEs [35], which is essential to achieve an all-in-one strategy against staphylococcal food poisoning (Table 1). For example, tomatidine is a well-known antibacterial compound with demonstrated activity against S. aureus [67]. Tomatidine is a steroidal alkaloid found in different solanaceous plants, which was first described as a bactericidal agent against small-colony variants of S. aureus [68]. However, tomatidine is also a quorum-sensing inhibitor, which alters the expression of many virulence factors, including some toxins [69]. Similarly, the expression of the staphylococcal α-toxin is controlled by allicin, capsaicin, and other amide-derived alkaloids present in chili peppers [35,70], another solanaceous plant.
Interestingly, anisodamine is an alkaloid produced by a Chinese herb that reduces the TSST-1 concentration in serum and the risk of toxic shock syndrome [71]. Anisodamine is an immunomodulator that inhibits the expression of cytokines such as tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1β), interleukin 8 (IL-8), interleukin 2 (IL-2), and interferon gamma (IFN-γ) expression in a dose-dependent manner, which may eventually reduce the effects of the cytokine storm induced during the toxic shock syndrome [71,72].
Table 1. Natural sources of active compounds that could be useful to prevent staphylococcal-food poisoning.
Table 1. Natural sources of active compounds that could be useful to prevent staphylococcal-food poisoning.
Natural SourcesActive CompoundsTargetsReferences
Muscadine grapeGallic and ellagic acidsS. aureus[62]
Chenopodium albumPhenolic compounds
Flavonoid compounds
S. aureus[66]
Citrus fruits, grapes, and tomatoesTomatidine
Naringenin
S. aureus[69,73,74]
Fermented orange juiceNaringenin-glycosylatedS. aureus[75]
GarlicAllicinS. aureus[70]
Chili peppersCapsaicinS. aureus[35]
Chinese herbsAnisodamineSEs[71]
Licorice rootLicochalcone AS. aureus[76]
Olive oil4-hydroxytyrosol
Tyrosol
Vanillic acid
p-coumaric acid
4-(acetoxyethyl)-1,2-dihydroxybenzene
Pinoresinol
1-acetoxypinoresinol
Salmonella enterica
Listeria monocytogenes
E. coli
S. aureus
[77,78,79,80,81,82,83]
Clove oilEugenolSEs[84]
WineResveratrol
Tannins
α-toxin[35,85]
MenthaMentholSEs[86]
Hop plantXanthohumolS. aureus[87]
MustardAllylisothiocyanateS. aureus
Pseudomonas aeruginosa
E. coli
L. monocytogenes
[88]
Aloe veraAloeemodinS. aureus[64]
Eucalyptus, MimosaPyroligenous acidsS. aureus
E. coli
P. aeruginosa
[89]
Caloboletus radicans8-deacetylcyclocalopinS. aureus[90]
Pleurotus sajor-cajup-hydroxybenzoic acid
p-coumaric acid
Cinnamic acid
S. aureus[90,91]
HoneyHydrogen peroxide
Gluconic acid
Polyphenols
Multiple bacteria
S. aureus
[92,93,94,95]
PropolisPolyphenols
Waxes
Resins
Polysaccharides
E. coli
S. aureus
[96,97]
Other natural sourcesCinnamaldehyde
Baicalein
Apicidin
α-cyperone
Avellanin C
Quorum sensing
S. aureus
Bacillus sp.
[64,98,99]
Moreover, phenolic compounds (in particular, many flavonoids) could be used to control the hemolytic activity and secretion of some SEs (Table 1). For example, licochalcone A may decrease the expression and secretion of SEA and SEB in a dose-dependent manner, and consequently, the release of TNF-α, which ameliorates the adverse effects of these enterotoxins [76].
Naringenin is another well-studied natural flavonoid that is present in citrus fruits and tomatoes. Naringenin presents a low antimicrobial activity against S. aureus, but it can also inhibit the α-toxin expression at subinhibitory concentrations [73,74]. However, the main handicap of naringenin is its low solubility and, therefore, low oral bioavailability. Nevertheless, the functionalization of the molecule with certain lipophilic groups may enhance its biochemical properties [100]. Furthermore, naringenin-glycosylated forms present in fermented orange juice increase this compound’s absorption profile from the diet [75].
Moreover, olive oil possesses many phenolic compounds with important antimicrobial activities, and therefore it is considered a great natural product used for food preservation [77]. The antimicrobial activity of commercial olive oil has been tested against many different bacterial pathogens (Table 1), showing activity against all of them in broth cultures when small quantities of olive oils are added [78].
The antimicrobial activity of polyphenols contained in olive oil has been clearly demonstrated [79,80,81]. For example, 4-hydroxytyrosol is a phenolic derivative found in olives that shows SEA-inhibition and bactericidal activity [82]. This compound may be found in plant crude extracts but also in edible olives. However, the polyphenols content can vary depending on the species used, the degree of maturation of its fruits, and the irrigation system used during olive cultivation [79,81].
Apart from 4-hydroxytyrosol, the most common phenolic compounds found in olive oil are tyrosol, vanillic acid, p-coumaric, 4-(acetoxyethyl)-1,2-dihydrxybenzene, pinoresinol, and 1-acetoxypinoresinol [77,79,80,81,83]. Due to its complex and variable composition, the olive oil’s polyphenols are collectively named olive oil polyphenol extract (OOPE).
Other plant-derived polyphenols include eugenol, which is found in clove oil and represses the expression of the genes that encode SEA, SEB, and TSST-1 at subinhibitory concentrations [84]. Wine-derived phenolic compounds such as the stilbenoids (e.g., resveratrol) and tannins showed anti-hemolytic activity [35,85]. Moreover, menthol is a terpene alcohol from plants of the Mentha genus that also inhibits the expression of genes encoding exotoxins, specially α-hemolysin, SEA, SEB, and TSST1 [86].
Besides, several compounds block biofilm formation or bacterial adhesion to host tissues that are important to reduce the virulence of S. aureus. For instance, the hop plant (Humulus lupulus) contains xanthohumol, which showed significant antimicrobial activity against S. aureus and inhibited its biofilm formation [87]. Moreover, allylisothiocyanate is the product responsible for the pungent taste of mustard, radish, or wasabi, and it is an efficient biofilm inhibitor of many different bacteria, including S. aureus [35,88]. There are many more antibiofilm compounds produced by plants, including terpenes, flavonoids, and other phenolic compounds, with variable effectiveness [35,101].
Other plant-derived compounds may exhibit broad anti-staphylococcal activities. For instance, aloeemodin is an inhibitor of the Accessory Gene Regulation C (AgrC) produced by aloe vera, which strongly impacts S. aureus because the AgrCA two-component system controls the expression of many virulence factors [64]. On the other hand, eucalyptus and mimosa plants produce pyroligneous acid (PA) with antiseptic activities that have been tested against several bacterial pathogens, including S. aureus [89,102].
Fungi are another very rich source of antimicrobial compounds that include terpenes, anthraquinones, quinolines, or benzoic acid derivatives (Table 1). For example, members of the genus Ganoderma produce many antimicrobial compounds that have been tested against S. aureus [90,103]. However, the lack of knowledge on the mechanism of action of these compounds is still impeding their application in the food industry.
Other European-distributed fungi such as Caloboletus radicans produce the anti-staphylococcal compounds 8-deacetylcyclocalopin [90]. In addition, Pleurotus sajor-caju produces acid compounds with anti-staphylococcal activity, such as p-hydroxybenzoic, p-coumaric, and cinnamic acids [90,91].
Honey is another well-studied natural product with antimicrobial activity [104]. Honey is composed mainly of sugars, but many other compounds are part of this natural product (Table 1). Firstly, its physiological characteristics, such as its acidity and low water activity, make it a challenging substrate for bacterial growth [92]. However, the complexity of honey composition and its components’ heterogeneity makes it difficult to compare and find the most active compounds with the highest antimicrobial potential [93]. Furthermore, the enzymatic conversion of glucose results in various compounds with antibacterial properties, such as hydrogen peroxide and gluconic acid, which show dose-dependent bactericidal effects [92,93,94,95].
Polyphenols are also key antimicrobial molecules present in honey, despite that the polyphenolic profile and its bioactivity changes significantly between many different types of honey [92,105]. Interestingly, the floral source of the honey seems to be a key factor influencing its composition of polyphenolic compounds and their antibacterial activity [106,107].
Wax propolis is another bee-derived product made basically of resins, waxes, polyphenols, polysaccharides, volatile materials, and secondary metabolites that show antibacterial, antioxidant, or antiviral activities [96]. Different propolis types have shown activity against different Gram-positive and Gram-negative bacteria, including S. aureus [97]. Similar to honey, the floral origin of the propolis determines its composition and antimicrobial activity.
Finally, many natural products inhibit the AgrC-based quorum sensing, biofilm formation, and cell-to-cell communication in S. aureus [64,65,108,109]. These compounds are frequently produced by fungi or plants and include cinnamaldehyde, baicalein, apicidin, α-cyperone, or avellanin C [64,98,99]. In addition, some bacteria with probiotic potential, such as Bacillus spp., may also produce very effective quorum-sensing inhibitors [110].

4. Conclusions

The incidence of antimicrobial-resistant bacterial infections is increasing worldwide, and the development of new antimicrobial therapies is not keeping pace with the acquisition and transmission of antibacterial resistance. S. aureus is one of the most important human pathogens, and it is quickly acquiring resistance to last-resort drugs used in clinical medicine. Moreover, staphylococci and their exotoxins are important sources of food contamination. There are many promising preventative and therapeutic strategies against staphylococcal food intoxications, but very few have been tested in vivo, and a limited number of clinical trials have been conducted with these compounds.
One of these exceptions is the flavonoid naringenin, which has been recently tested in clinical trials [111]. However, naringenin has a low oral bioavailability; thus, new naringenin-glycosylated derivatives are currently developed to improve its absorption profile. Many other natural compounds with antimicrobial activity against staphylococci have only been tested in preclinical trials due to their low absorption, distribution, metabolism, or excretion properties.
Nevertheless, the natural products with antimicrobial activity against staphylococci have the potential to be used as food additives alone or in combination to prevent food-poisonings. However, more research is required to test the dosage and stability of the compounds with the best antimicrobial profiles.
Plant-derived polyphenols are one of the most important sources of antimicrobial compounds with activity against S. aureus. Flavonoids, terpenoids, and other important antimicrobial compounds could be found in citrus fruits, grapes, honey, garlic, and other inexpensive food that undoubtedly may impact the incidence of staphylococcal food intoxications and the spread of antimicrobial resistance. Combining different natural compounds could enhance their antimicrobial or antitoxin activities, but more research is needed to evaluate their possible synergistic effects.

Author Contributions

Á.M. wrote the first draft of the manuscript. Á.M., J.A.G., L.M.M., and M.L. contributed to manuscript edition, revision, read, and approved the submitted version. All authors have read and agreed to the published version of the manuscript.

Funding

We want to thank the Junta de Castilla y León (Spain) for funding our research work (Ref. LE044P20).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Acknowledgments

We are thankful to the anonymous reviewers for reading our manuscript and their insightful comments and suggestions.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Hennekinne, J.A.; De Buyser, M.L.; Dragacci, S. Staphylococcus aureus and its food poisoning toxins: Characterization and outbreak investigation. FEMS Microbiol. Rev. 2012, 36, 815–836. [Google Scholar] [CrossRef] [Green Version]
  2. Chajęcka-Wierzchowska, W.; Gajewska, J.; Wiśniewski, P.; Zadernowska, A. Enterotoxigenic potential of coagulase-negative staphylococci from ready-to-eat food. Pathogens 2020, 9, 734. [Google Scholar] [CrossRef] [PubMed]
  3. Lyra, D.G.; Sousa, F.G.C.; Borges, M.F.; Givisiez, P.E.N.; Queiroga, R.C.R.E.; Souza, E.L.; Gebreyes, W.A.; Oliveira, C.J.B. Enterotoxin-encoding genes in Staphylococcus spp. from bulk goat milk. Foodborne Pathog. Dis. 2013, 10, 126–130. [Google Scholar] [CrossRef]
  4. De Andrade, A.P.C.; De Fátimaborges, M.; de Figueiredo, E.A.T.; Arcuri, E.F. Diversity of Staphylococcus coagulase-positive and negative strains of coalho cheese and detection of enterotoxin encoding genes. Embrapa Agroindústria Trop. Artig. Periódico Indexado 2019, 36, 1–9. [Google Scholar]
  5. Schubert, J.; Podkowik, M.; Bystroń, J.; Bania, J. Production of staphylococcal enterotoxins in microbial broth and milk by Staphylococcus aureus strains harboring seh gene. Int. J. Food Microbiol. 2016, 235, 36–45. [Google Scholar] [CrossRef] [PubMed]
  6. Ewida, R.M.; Al-Hosary, A.A.T. Prevalence of enterotoxins and other virulence genes of Staphylococcus aureus caused subclinical mastitis in dairy cows. Vet. World 2020, 13, 1193–1198. [Google Scholar] [CrossRef]
  7. Le Loir, Y.; Baron, F.; Gautier, M. Staphylococcus aureus and food poisoning. Genet. Mol. Res. 2003, 2, 63–76. [Google Scholar] [PubMed]
  8. Pinchuk, I.V.; Beswick, E.J.; Reyes, V.E. Staphylococcal enterotoxins. Toxins 2010, 2, 2177–2197. [Google Scholar] [CrossRef] [Green Version]
  9. Grispoldi, L.; Popescu, P.A.; Karama, M.; Gullo, V.; Poerio, G.; Borgogni, E.; Torlai, P.; Chianese, G.; Fermani, A.G.; Sechi, P.; et al. Study on the growth and enterotoxin production by Staphylococcus aureus in canned meat before retorting. Toxins 2019, 11, 291. [Google Scholar] [CrossRef] [Green Version]
  10. Suzuki, Y.; Ono, H.K.; Shimojima, Y.; Kubota, H.; Kato, R.; Kakuda, T.; Hirose, S.; Hu, D.L.; Nakane, A.; Takai, S.; et al. A novel staphylococcal enterotoxin SE02 involved in a staphylococcal food poisoning outbreak that occurred in Tokyo in 2004. Food Microbiol. 2020, 92, 103588. [Google Scholar] [CrossRef]
  11. Castro, A.; Santos, C.; Meireles, H.; Silva, J.; Teixeira, P. Food handlers as potential sources of dissemination of virulent strains of Staphylococcus aureus in the community. J. Infect. Public Health 2016, 9, 153–160. [Google Scholar] [CrossRef] [Green Version]
  12. Li, H.; Tang, T.; Stegger, M.; Dalsgaard, A.; Liu, T.; Leisner, J.J. Characterization of antimicrobial-resistant Staphylococcus aureus from retail foods in Beijing, China. Food Microbiol. 2021, 93, 103603. [Google Scholar] [CrossRef] [PubMed]
  13. Mama, O.M.; Gómez-Sanz, E.; Ruiz-Ripa, L.; Gómez, P.; Torres, C. Diversity of staphylococcal species in food producing animals in Spain, with detection of PVL-positive MRSA ST8 (USA300). Vet. Microbiol. 2019, 233, 5–10. [Google Scholar] [CrossRef] [PubMed]
  14. Chiang, Y.C.; Liao, W.W.; Fan, C.M.; Pai, W.Y.; Chiou, C.S.; Tsen, H.Y. PCR detection of Staphylococcal enterotoxins (SEs) N, O, P, Q, R, U, and survey of SE types in Staphylococcus aureus isolates from food-poisoning cases in Taiwan. Int. J. Food Microbiol. 2008, 121, 66–73. [Google Scholar] [CrossRef] [PubMed]
  15. Schelin, J.; Susilo, Y.B.; Johler, S. Expression of staphylococcal enterotoxins under stress encountered during food production and preservation. Toxins 2017, 9, 401. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Silva, G.O.; Castro, R.D.; Oliveira, L.G.; Sant’Anna, F.M.; Barbosa, C.D.; Sandes, S.H.C.; Silva, R.S.; Resende, M.F.S.; Lana, A.M.Q.; Nunes, A.C.; et al. Viability of Staphylococcus aureus and expression of its toxins (SEC and TSST-1) in cheeses using Lactobacillus rhamnosus D1 or Weissella paramesenteroides GIR16L4 or both as starter cultures. J. Dairy Sci. 2020, 103, 4100–4108. [Google Scholar] [CrossRef]
  17. Nasaj, M.; Saeidi, Z.; Tahmasebi, H.; Dehbashi, S.; Arabestani, M. Prevalence and Distribution of Resistance and Enterotoxins/Enterotoxin-likes Genes in Different Clinical Isolates of Coagulase-negative Staphylococcus. Eur. J. Med. Res. 2020, 1–11. [Google Scholar] [CrossRef]
  18. Do Carmo, L.S.; Dias, R.S.; Linardi, V.R.; De Sena, M.J.; Dos Santos, D.A.; De Faria, M.E.; Pena, E.C.; Jett, M.; Heneine, L.G. Food poisoning due to enterotoxigenic strains of Staphylococcus present in Minas cheese and raw milk in Brazil. Food Microbiol. 2002, 19, 9–14. [Google Scholar] [CrossRef]
  19. Loncaric, I.; Kübber-heiss, A.; Posautz, A.; Ruppitsch, W.; Lepuschitz, S.; Schauer, B.; Feßler, A.T.; Krametter-frötscher, R.; Harrison, E.M.; Holmes, M.A.; et al. Characterization of mecC gene-carrying coagulase-negative Staphylococcus spp. isolated from various animals. Vet. Microbiol. 2019, 230, 138–144. [Google Scholar] [CrossRef]
  20. Morris, D.O.; Loeffler, A.; Davis, M.F.; Guardabassi, L.; Weese, J.S. Recommendations for approaches to meticillin-resistant staphylococcal infections of small animals: Diagnosis, therapeutic considerations and preventative measures.: Clinical Consensus Guidelines of the World Association for Veterinary Dermatology. Vet. Dermatol. 2017, 28. [Google Scholar] [CrossRef]
  21. Bora, P.; Datta, P.; Gupta, V.; Singhal, L.; Chander, J. Characterization and antimicrobial susceptibility of coagulase-negative staphylococci isolated from clinical samples. J. Lab. Physicians 2018, 10, 414–419. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Spaulding, A.R.; Salgado-Pabón, W.; Kohler, P.L.; Horswill, A.R.; Leung, D.Y.M.; Schlievert, P.M. Staphylococcal and streptococcal superantigen exotoxins. Clin. Microbiol. Rev. 2013, 26, 422–447. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Bachert, C.; Gevaert, P.; van Cauwenberge, P. Staphylococcus aureus superantigens and airway disease. Curr. Allergy Asthma Rep. 2002, 2, 252–258. [Google Scholar] [CrossRef] [PubMed]
  24. Krakauer, T. Staphylococcal superantigens: Pyrogenic toxins induce toxic shock. Toxins 2019, 11, 178. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Aman, M.J. Superantigens of a superbug: Major culprits of Staphylococcus aureus disease? Virulence 2017, 8, 607–610. [Google Scholar] [CrossRef] [Green Version]
  26. Krakauer, T.; Stiles, B.G. The staphylococcal enterotoxin (SE) family: SEB and siblings. Virulence 2013, 4, 759–773. [Google Scholar] [CrossRef] [Green Version]
  27. Zhang, X.; Hu, X.; Rao, X. Apoptosis induced by Staphylococcus aureus toxins. Microbiol. Res. 2017, 205, 19–24. [Google Scholar] [CrossRef]
  28. Salgado-Pabón, W.; Breshears, L.; Spaulding, A.R.; Merriman, J.A.; Stach, C.S.; Horswill, A.R.; Peterson, M.L.; Schlievert, P.M. Superantigens are critical for Staphylococcus aureus infective endocarditis, sepsis, and acute kidney injury. MBio 2013, 4, 1–9. [Google Scholar] [CrossRef] [Green Version]
  29. Benkerroum, N. Staphylococcal enterotoxins and enterotoxin-like toxins with special reference to dairy products: An overview. Crit. Rev. Food Sci. Nutr. 2018, 58, 1943–1970. [Google Scholar] [CrossRef]
  30. Strandberg, K.L.; Rotschafer, J.H.; Vetter, S.M.; Buonpane, R.A.; Kranz, D.M.; Schlievert, P.M. Staphylococcal superantigens cause lethal pulmonary disease in rabbits. J. Infect. Dis. 2010, 202, 1690–1697. [Google Scholar] [CrossRef] [Green Version]
  31. Adame-Gómez, R.; Castro-Alarcón, N.; Vences-Velázquez, A.; Toribio-Jiménez, J.; Pérez-Valdespino, A.; Leyva-Vázquez, M.A.; Ramírez-Peralta, A. Genetic Diversity and Virulence Factors of S. aureus Isolated from Food, Humans, and Animals. Int. J. Microbiol. 2020, 2020. [Google Scholar] [CrossRef] [PubMed]
  32. Vaughn, J.M.; Abdi, R.D.; Gillespie, B.E.; Dego, O.K. Genetic diversity and virulence characteristics of Staphylococcus aureus isolates from cases of bovine mastitis. Microb. Pathog. 2020, 144, 104171. [Google Scholar] [CrossRef] [PubMed]
  33. Shettigar, K.; Murali, T.S. Virulence factors and clonal diversity of Staphylococcus aureus in colonization and wound infection with emphasis on diabetic foot infection. Eur. J. Clin. Microbiol. Infect. Dis. 2020, 39, 2235–2246. [Google Scholar] [CrossRef] [PubMed]
  34. Horn, J.; Klepsch, M.; Manger, M.; Wolz, C.; Rudel, T.; Fraunholz, M. Long noncoding RNA SSR42 controls Staphylococcus aureus alpha-toxin transcription in response to environmental stimuli. J. Bacteriol. 2018, 200, e00252-18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Silva, L.N.; Zimmer, K.R.; Macedo, A.J.; Trentin, D.S. Plant natural products targeting bacterial virulence factors. Chem. Rev. 2016, 116, 9162–9236. [Google Scholar] [CrossRef]
  36. Chan, W.T.; Balsa, D.; Espinosa, M. One cannot rule them all: Are bacterial toxins-antitoxins druggable? FEMS Microbiol. Rev. 2015, 39, 522–540. [Google Scholar] [CrossRef] [Green Version]
  37. Williams, J.J.; Hergenrother, P.J. Artificial activation of toxin-antitoxin systems as an antibacterial strategy. Trends Microbiol. 2012, 20, 291–298. [Google Scholar] [CrossRef] [Green Version]
  38. Sergelidis, D.; Angelidis, A.S. Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study. Lett. Appl. Microbiol. 2017, 64, 409–418. [Google Scholar] [CrossRef] [Green Version]
  39. Rasigade, J.P. Catching the evader: Can monoclonal antibodies interfere with Staphylococcus aureus immune escape? Virulence 2018, 9, 1–4. [Google Scholar] [CrossRef] [Green Version]
  40. Pier, G.B. Will there ever be a universal Staphylococcus aureus vaccine? Hum. Vaccines Immunother. 2013, 9, 1865–1876. [Google Scholar] [CrossRef] [Green Version]
  41. Fowler, V.G.; Proctor, R.A. Where does a Staphylococcus aureus vaccine stand? Clin. Microbiol. Infect. 2014, 20, 66–75. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Miller, L.S.; Fowler, V.G.; Shukla, S.K.; Rose, W.E.; Proctor, R.A. Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms. FEMS Microbiol Rev. 2020, 44, 123–153. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Adhikari, R.P.; Ajao, A.O.; Aman, M.J.; Karauzum, H.; Sarwar, J.; Lydecker, A.D.; Johnson, J.K.; Nguyen, C.; Chen, W.H.; Roghmann, M.C. Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J. Infect. Dis. 2012, 206, 915–923. [Google Scholar] [CrossRef] [PubMed]
  44. Otto, M. Staphylococcus colonization of the skin and antimicrobial peptides. Expert Rev Dermatol. 2010, 5, 183–195. [Google Scholar] [CrossRef] [Green Version]
  45. Zurawski, D.V.; McLendon, M.K. Monoclonal antibodies as an antibacterial approach against bacterial pathogens. Antibiotics 2020, 9, 155. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Luciani, M.; Iannetti, L. Monoclonal antibodies and bacterial virulence. Virulence 2017, 8, 635–636. [Google Scholar] [CrossRef] [Green Version]
  47. Raafat, D.; Otto, M.; Iqbal, J.; Holtfreter, S.; Section, M.G.; Diseases, I. Fighting Staphylococcus aureus biofilms with monoclonal antibodies. Trends Microbiol. 2019, 27, 303–322. [Google Scholar] [CrossRef]
  48. Verkaik, N.J.; Van Wamel, W.J.; Van Belkum, A. Immunotherapeutic approaches against Staphylococcus aureus. Immunotherapy 2011, 3, 1063–1073. [Google Scholar] [CrossRef]
  49. Yang, Y.; Qian, M.; Yi, S.; Liu, S.; Li, B.; Yu, R.; Guo, Q.; Zhang, X.; Yu, C.; Li, J.; et al. Monoclonal antibody targeting Staphylococcus aureus surface protein A (SasA) protect against Staphylococcus aureus sepsis and peritonitis in mice. PLoS ONE 2016, 11, e0149460. [Google Scholar] [CrossRef] [Green Version]
  50. Liu, B.; Park, S.; Thompson, C.D.; Li, X.; Lee, J.C. Antibodies to Staphylococcus aureus capsular polysaccharides 5 and 8 perform similarly in vitro but are functionally distinct in vivo. Virulence 2017, 8, 859–874. [Google Scholar] [CrossRef] [Green Version]
  51. Aguilar, J.L.; Varshney, A.K.; Pechuan, X.; Dutta, K.; Nosanchuk, J.D.; Fries, B.C. Monoclonal antibodies protect from staphylococcal enterotoxin K (SEK) induced toxic shock and sepsis by USA300 Staphylococcus aureus. Virulence 2017, 8, 741–750. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Chen, G.; Karauzum, H.; Long, H.; Carranza, D.; Holtsberg, F.W.; Howell, K.A.; Abaandou, L.; Zhang, B.; Jarvik, N.; Ye, W.; et al. Potent neutralization of staphylococcal enterotoxin B in vivo by antibodies that block binding to the T-cell receptor. J. Mol. Biol. 2019, 431, 4354–4367. [Google Scholar] [CrossRef] [PubMed]
  53. Mourenza, Á.; Gil, J.A.; Mateos, L.M.; Letek, M. Alternative anti-infective treatments to traditional antibiotherapy against staphylococcal veterinary pathogens. Antibiotics 2020, 9, 702. [Google Scholar] [CrossRef] [PubMed]
  54. Fritz, S.A.; Tiemann, K.M.; Hogan, P.G.; Epplin, E.K.; Rodriguez, M.; Al-Zubeidi, D.N.; Wardenburg, J.B.; Hunstad, D.A. A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection. Clin. Infect. Dis. 2013, 56, 1554–1561. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Adhikari, R.P.; Karauzum, H.; Sarwar, J.; Abaandou, L.; Mahmoudieh, M.; Boroun, A.R.; Vu, H.; Nguyen, T.; Devi, V.S.; Shulenin, S.; et al. Novel structurally designed vaccine for S. aureus α-hemolysin: Protection against bacteremia and pneumonia. PLoS ONE 2012, 7. [Google Scholar] [CrossRef]
  56. Bonventre, P.F.; Linnemann, C.; Weckbach, L.S.; Staneck, J.L.; Buncher, C.R.; Vigdorth, E.; Ritz, H.; Archer, D.; Smith, B. Antibody responses to toxic-shock-syndrome (TSS) toxin by patients with TSS and by healthy staphylococcal carriers. J. Infect. Dis. 1984, 150, 662–666. [Google Scholar] [CrossRef]
  57. Stolz, S.J.; Davis, J.P.; Vergeront, J.M.; Crass, B.A.; Chesney, P.J.; Wand, P.J.; Bergdoll, M.S. Development of serum antibody to toxic shock toxin among individuals with toxic shock syndrome in wisconsin. J. Infect. Dis. 1985, 151, 883–889. [Google Scholar] [CrossRef]
  58. Vergeront, J.M.; Stolz, S.J.; Crass, B.A.; Nelson, D.B.; Davis, J.P.; Bergdoll, M.S. Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: Implications for toxic-shock syndrome. J. Infect. Dis. 1983, 148, 692–698. [Google Scholar] [CrossRef]
  59. Roetzer, A.; Stich, N.; Model, N.; Schwameis, M.; Firbas, C.; Jilma, B.; Eibl, M.M. High titer persistent neutralizing antibodies induced by TSST-1 variant vaccine against toxic shock cytokine storm. Toxins 2020, 12, 640. [Google Scholar] [CrossRef]
  60. Hu, D.L.; Omoe, K.; Sasaki, S.; Sashinami, H.; Sakuraba, H.; Yokomizo, Y.; Shinagawa, K.; Nakane, A. Vaccination with non-toxic mutant toxic shock syndrome toxin-1 induces IL-17-dependent protection against Staphylococcus aureus infection. J. Infect. Dis. 2003, 188, 743–752. [Google Scholar] [CrossRef] [Green Version]
  61. Bennett, M.R.; Dong, J.; Bombardi, R.G.; Soto, C.; Parrington, H.M.; Nargi, R.S.; Schoeder, C.T.; Nagel, M.B.; Schey, K.L.; Meiler, J.; et al. Human VH1-69 gene-encoded human monoclonal antibody against Staphylococcus aureus IsdB use at least three distinct pathogenesis. MBio 2019, 10, 1–14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  62. Xu, C.; Yagiz, Y.; Hsu, W.Y.; Simonne, A.; Lu, J.; Marshall, M.R. Antioxidant, antibacterial, and antibiofilm properties of polyphenols from muscadine grape (Vitis rotundifolia Michx.) Pomace against selected foodborne pathogens. J. Agric. Food Chem. 2014, 62, 6640–6649. [Google Scholar] [CrossRef] [PubMed]
  63. Harro, J.M.; Peters, B.M.; O’May, G.A.; Archer, N.; Kerns, P.; Prabhakara, R.; Shirtliff, M.E. Vaccine development in Staphylococcus aureus: Taking the biofilm phenotype into consideration. FEMS Immunol. Med. Microbiol. 2010, 59, 306–323. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Wu, S.C.; Liu, F.; Zhu, K.; Shen, J.Z. Natural products that target virulence factors in antibiotic-resistant Staphylococcus aureus. J. Agric. Food Chem. 2019, 67, 13195–13211. [Google Scholar] [CrossRef] [PubMed]
  65. Defoirdt, T. Antivirulence therapy for animal production: Filling an arsenal with novel weapons for sustainable disease control. PLoS Pathog. 2013, 9, e1003603. [Google Scholar] [CrossRef] [PubMed]
  66. Said, A.; Naeem, N.; Siraj, S.; Khan, T.; Javed, A.; Rasheed, H.M.; Sajjad, W.; Shah, K.; Wahid, F. Mechanisms underlying the wound healing and tissue regeneration properties of Chenopodium album. 3 Biotech 2020, 10, 452. [Google Scholar] [CrossRef]
  67. Boulet, M.L.; Charles, I.; Guay, I.; Brouillette, E.; Langlois, J.-P.; Jacques, P.; Rodrigue, S.; Brzezinski, R.; Beauregard, P.B.; Bouarab, K. Tomatidine is a lead antibiotic molecule that targets Staphylococcus aureus ATP synthasesubunit C. Antimicrob. Agents Chemother. 2018, 62, 1–18. [Google Scholar]
  68. Mitchell, G.; Gattuso, M.; Grondin, G.; Marsault, É.; Bouarab, K.; Malouin, F. Tomatidine inhibits replication of Staphylococcus aureus small-colony variants in cystic fibrosis airway epithelial cells. Antimicrob. Agents Chemother. 2011, 55, 1937–1945. [Google Scholar] [CrossRef] [Green Version]
  69. Mitchell, G.; Lafrance, M.; Boulanger, S.; Séguin, D.L.; Guay, I.; Gattuso, M.; Marsault, É.; Bouarab, K.; Malouin, F. Tomatidine acts in synergy with aminoglycoside antibiotics against multiresistant Staphylococcus aureus and prevents virulence gene expression. J. Antimicrob. Chemother. 2012, 67, 559–568. [Google Scholar] [CrossRef] [Green Version]
  70. Leng, B.F.; Qiu, J.Z.; Dai, X.H.; Dong, J.; Wang, J.F.; Luo, M.J.; Li, H.E.; Niu, X.-D.; Zhang, Y.; Ai, Y.X.; et al. Allicin reduces the production of α-toxin by Staphylococcus aureus. Molecules 2011, 16, 7958–7968. [Google Scholar] [CrossRef] [Green Version]
  71. Nakagawa, S.; Kushiya, K.; Taneike, I.; Imanishi, K.; Uchiyama, T.; Yamamoto, T. Specific inhibitory action of anisodamine against a staphylococcal superantigenic toxin, toxic shock syndrome toxin 1 (TSST-1), leading to down-regulation of cytokine production and blocking of TSST-1 toxicity in mice. Clin. Diagn. Lab. Immunol. 2005, 12, 399–408. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Zhang, H.M.; Ou, Z.L.; Gondaira, F.; Ohmura, M.; Kojio, S.; Yamamoto, T. Protective effect of anisodamine against Shiga toxin-1: Inhibition of cytokine production and increase in the survival of mice. J. Lab. Clin. Med. 2001, 137, 93–100. [Google Scholar] [CrossRef] [PubMed]
  73. Kong, C.; Neoh, H.M.; Nathan, S. Targeting Staphylococcus aureus toxins: A potential form of anti-virulence therapy. Toxins 2016, 8, 72. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Zhang, Y.; Wang, J.F.; Dong, J.; Wei, J.Y.; Wang, Y.N.; Dai, X.H.; Wang, X.; Luo, M.J.; Tan, W.; Deng, X.M.; et al. Inhibition of α-toxin production by subinhibitory concentrations of naringenin controls Staphylococcus aureus pneumonia. Fitoterapia 2013, 86, 92–99. [Google Scholar] [CrossRef]
  75. Castello, F.; Fernández-Pachón, M.S.; Cerrillo, I.; Escudero-López, B.; Ortega, Á.; Rosi, A.; Bresciani, L.; Del Rio, D.; Mena, P. Absorption, metabolism, and excretion of orange juice (poly)phenols in humans: The effect of a controlled alcoholic fermentation. Arch. Biochem. Biophys. 2020, 695. [Google Scholar] [CrossRef]
  76. Qiu, J.; Feng, H.; Xiang, H.; Wang, D.; Xia, L.; Jiang, Y.; Song, K.; Lu, J.; Yu, L.; Deng, X. Influence of subinhibitory concentrations of licochalcone A on the secretion of enterotoxins A and B by Staphylococcus aureus. FEMS Microbiol. Lett. 2010, 307, 135–141. [Google Scholar] [CrossRef] [Green Version]
  77. Guo, L.; Gong, S.; Wang, Y.; Sun, Q.; Duo, K.; Fei, P. Antibacterial Activity of Olive Oil Polyphenol Extract Against Salmonella Typhimurium and Staphylococcus aureus: Possible Mechanisms. Foodborne Pathog. Dis. 2020, 17, 396–403. [Google Scholar] [CrossRef]
  78. Medina, E.; Romero, C.; Brenes, M.; De Castro, A. Antimicrobial activity of olive oil, vinegar, and various beverages against foodborne pathogens. J. Food Prot. 2007, 70, 1194–1199. [Google Scholar] [CrossRef]
  79. Brenes, M.; García, A.; García, P.; Rios, J.J.; Garrido, A. Phenolic compounds in Spanish olive oils. J. Agric. Food Chem. 1999, 47, 3535–3540. [Google Scholar] [CrossRef]
  80. Brenes, M.; Hidalgo, F.J.; García, A.; Rios, J.J.; García, P.; Zamora, R.; Garrido, A. Pinoresinol and 1-acetoxypinoresinol, two new phenolic compounds identified in olive oil. JAOCS J. Am. Oil Chem. Soc. 2000, 77, 715–720. [Google Scholar] [CrossRef]
  81. Tovar, M.J.; Motilva, M.J.; Romero, M.P. Changes in the phenolic composition of virgin olive oil from young trees (Olea europaea L. cv. Arbequina) grown under linear irrigation strategies. J. Agric. Food Chem. 2001, 49, 5502–5508. [Google Scholar] [CrossRef] [PubMed]
  82. Friedman, M.; Rasooly, R.; Do, P.M.; Henika, P.R. The Olive Compound 4-Hydroxytyrosol Inactivates Staphylococcus aureus Bacteria and Staphylococcal Enterotoxin A (SEA). J. Food Sci. 2011, 76. [Google Scholar] [CrossRef] [PubMed]
  83. García-Martínez, O.; De Luna-Bertos, E.; Ramos-Torrecillas, J.; Ruiz, C.; Milia, E.; Lorenzo, M.L.; Jimenez, B.; Sánchez-Ortiz, A.; Rivas, A. Phenolic compounds in extra virgin olive oil stimulate human osteoblastic cell proliferation. PLoS ONE 2016, 11, e0150045. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Qiu, J.; Feng, H.; Lu, J.; Xiang, H.; Wang, D.; Dong, J.; Wang, J.; Wang, X.; Liu, J.; Deng, X. Eugenol reduces the expression of virulence-related exoproteins in Staphylococcus aureus. Appl. Environ. Microbiol. 2010, 76, 5846–5851. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  85. Kiran, M.D.; Adikesavan, N.V.; Cirioni, O.; Giacometti, A.; Silvestri, C.; Scalise, G.; Ghiselli, R.; Saba, V.; Orlando, F.; Shoham, M.; et al. Discovery of a quorum-sensing inhibitor of drug-resistant staphylococcal infections by structure-based virtual screening. Mol. Pharmacol. 2008, 73, 1578–1586. [Google Scholar] [CrossRef] [Green Version]
  86. Qiu, J.; Luo, M.; Dong, J.; Wang, J.; Li, H.; Wang, X.; Deng, Y.; Feng, H.; Deng, X. Menthol diminishes Staphylococcus aureus virulence-associated extracellular proteins expression. Appl. Microbiol. Biotechnol. 2011, 90, 705–712. [Google Scholar] [CrossRef]
  87. Rozalski, M.; Micota, B.; Sadowska, B.; Stochmal, A.; Jedrejek, D.; Wieckowska-Szakiel, M.; Rozalska, B. Antiadherent and antibiofilm activity of Humulus lupulus L. derived products: New pharmacological properties. Biomed Res. Int. 2013, 2013, 101089. [Google Scholar] [CrossRef] [Green Version]
  88. Borges, A.; Simoes, L.C.; Saavedra, M.J.; Simoes, M. The action of selected isothiocyanates on bacterial biofilm prevention and control. Int. Biodeterior. Biodegrad. 2014, 86, 25–33. [Google Scholar] [CrossRef] [Green Version]
  89. Soares, W.N.C.; de Oliveira, L.G.P.; Santos, C.S.; Dias, G.N.; Pimenta, A.S.; Pereira, A.F.; Moreira, L.D.; Marlon, F.; Feijó, C. Pyroligneous acid from Mimosa tenuiflora and Eucalyptus urograndis as an antimicrobial in dairy goats. J. Appl. Microbiol. 2020. [Google Scholar] [CrossRef]
  90. Vallavan, V.; Krishnasamy, G.; Zin, N.M.; Latif, M.A. A review on antistaphylococcal secondary metabolites from Basidiomycetes. Molecules 2020, 25, 5848. [Google Scholar] [CrossRef]
  91. Finimundy, T.C.; Barros, L.; Calhelha, R.C.; Alves, M.J.; Prieto, M.A.; Abreu, R.M.V.; Dillon, A.J.P.; Henriques, J.A.P.; Roesch-Ely, M.; Ferreira, I.C.F.R. Multifunctions of Pleurotus sajor-caju (Fr.) Singer: A highly nutritious food and a source for bioactive compounds. Food Chem. 2018, 245, 150–158. [Google Scholar] [CrossRef] [Green Version]
  92. Combarros-fuertes, P.; Fresno, J.M.; Estevinho, M.M.; Sousa-Pimenta, M.; Tornadijo, M.E.; Estevinho, L.M. Honey: Another alternative in the fight against antibiotic-resistant bacteria? Antibiotics 2020, 9, 774. [Google Scholar] [CrossRef] [PubMed]
  93. Masoura, M.; Passaretti, P.; Overton, T.W.; Lund, P.A. Use of a model to understand the synergies underlying the antibacterial mechanism of H2O2-producing honeys. Sci. Rep. 2020, 10, 17692. [Google Scholar] [CrossRef] [PubMed]
  94. Fyfe, L.; Okoro, P.; Paterson, E.; Coyle, S.; McDougall, G.J. Compositional analysis of Scottish honeys with antimicrobial activity against antibiotic-resistant bacteria reveals novel antimicrobial components. LWT Food Sci. Technol. 2017, 79, 52–59. [Google Scholar] [CrossRef]
  95. Godocikova, J.; Bugarova, V.; Kast, C.; Majtan, V.; Majtan, J. Antibacterial potential of Swiss honeys and characterisation of their bee-derived bioactive compounds. J. Sci. Food Agric. 2020, 100, 335–342. [Google Scholar] [CrossRef] [PubMed]
  96. Almuhayawi, M.S. Propolis as a novel antibacterial agent. Saudi J. Biol. Sci. 2020, 27, 3079–3086. [Google Scholar] [CrossRef] [PubMed]
  97. Przybyłek, I.; Karpiński, T.M. Antibacterial properties of propolis. Molecules 2019, 24, 2047. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  98. Luo, M.; Qiu, J.; Zhang, Y.; Wang, J.; Dong, J.; Li, H.; Leng, B.; Zhang, Q.; Dai, X.; Niu, X.; et al. α-Cyperone alleviates lung cell injury caused by Staphylococcus aureus via attenuation of α-Hemolysin expression. J. Microbiol. Biotechnol. 2012, 22, 1170–1176. [Google Scholar] [CrossRef]
  99. Igarashi, Y.; Gohda, F.; Kadoshima, T.; Fukuda, T.; Hanafusa, T.; Shojima, A.; Nakayama, J.; Bills, G.F.; Peterson, S. Avellanin C, an inhibitor of quorum-sensing signaling in Staphylococcus aureus, from Hamigera ingelheimensis. J. Antibiot. 2015, 68, 707–710. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  100. de Oliveira, M.L.A.; Ponciano, C.S.; Cataneo, A.H.D.; Wowk, P.F.; Bordignon, J.; Silva, H.; de Almeida, M.V.; Ávila, E.P. The anti-Zika virus and anti-tumoral activity of the citrus flavanone lipophilic naringenin-based compounds. Chem. Biol. Interact. 2020, 331. [Google Scholar] [CrossRef]
  101. Guzzo, F.; Scognamiglio, M.; Fiorentino, A.; Buommino, E.; D’Abrosca, B. Plant Derived Natural Products against Pseudomonas aeruginosa and Staphylococcus aureus: Antibiofilm Activity and Molecular Mechanisms. Molecules 2020, 25, 24. [Google Scholar] [CrossRef] [PubMed]
  102. Suresh, G.; Pakdel, H.; Rouissi, T.; Brar, S.K.; Fliss, I.; Roy, C. In vitro evaluation of antimicrobial efficacy of pyroligneous acid from softwood mixture. Biotechnol. Res. Innov. 2019, 3, 47–53. [Google Scholar] [CrossRef]
  103. Bhosle, S.; Ranadive, K.; Bapat, G.; Garad, S.; Deshpande, G.; Vaidya, J. Taxonomy and diversity of Ganoderma from the western parts of Maharashtra (India). Mycosphere 2010, 1, 249–262. [Google Scholar]
  104. Nolan, V.C.; Harrison, J.; Wright, J.E.E.; Cox, J.A.G. Clinical significance of manuka and medical-grade honey for antibiotic-resistant infections: A systematic review. Antibiotics 2020, 9, 766. [Google Scholar] [CrossRef] [PubMed]
  105. Combarros-Fuertes, P.; Estevinho, L.M.; Dias, L.G.; Castro, J.M.; Tomás-Barberán, F.A.; Tornadijo, M.E.; Fresno-Baro, J.M. Bioactive Components and Antioxidant and Antibacterial Activities of Different Varieties of Honey: A Screening Prior to Clinical Application. J. Agric. Food Chem. 2019, 67, 688–698. [Google Scholar] [CrossRef] [Green Version]
  106. Sousa, J.M.; de Souza, E.L.; Marques, G.; Meireles, B.; de Magalhães, C.Â.T.; Gullón, B.; Pintado, M.M.; Magnani, M. Polyphenolic profile and antioxidant and antibacterial activities of monofloral honeys produced by Meliponini in the Brazilian semiarid region. Food Res. Int. 2016, 84, 61–68. [Google Scholar] [CrossRef]
  107. Bucekova, M.; Jardekova, L.; Juricova, V.; Bugarova, V.; Di Marco, G.; Gismondi, A.; Leonardi, D.; Farkasovska, J.; Godocikova, J.; Laho, M.; et al. Antibacterial activity of different blossom honeys: New findings. Molecules 2019, 24, 1573. [Google Scholar] [CrossRef] [Green Version]
  108. Cegelski, L.; Marshall, G.R.; Eldridge, G.R.; Hultgren, S.J. The biology and future prospects of antivirulence therapies. Nat. Rev. Microbiol. 2008, 6, 17–27. [Google Scholar] [CrossRef]
  109. Otto, M. Quorum-sensing control in Staphylococci—A target for antimicrobial drug therapy? FEMS Microbiol. Lett. 2004, 241, 135–141. [Google Scholar] [CrossRef]
  110. Piewngam, P.; Zheng, Y.; Nguyen, T.H.; Dickey, S.W.; Joo, H.; Villaruz, A.E.; Glose, K.A.; Fisher, E.L.; Hunt, R.L.; Li, B.; et al. Pathogen elimination by probiotic Bacillus via signaling interference. Nature 2018, 562, 532–537. [Google Scholar] [CrossRef]
  111. Salehi, B.; Fokou, P.V.T.; Sharifi-Rad, M.; Zucca, P.; Pezzani, R.; Martins, N.; Sharifi-Rad, J. The therapeutic potential of naringenin: A review of clinical trials. Pharmaceuticals 2019, 12, 11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Mourenza, Á.; Gil, J.A.; Mateos, L.M.; Letek, M. Novel Treatments and Preventative Strategies Against Food-Poisoning Caused by Staphylococcal Species. Pathogens 2021, 10, 91. https://doi.org/10.3390/pathogens10020091

AMA Style

Mourenza Á, Gil JA, Mateos LM, Letek M. Novel Treatments and Preventative Strategies Against Food-Poisoning Caused by Staphylococcal Species. Pathogens. 2021; 10(2):91. https://doi.org/10.3390/pathogens10020091

Chicago/Turabian Style

Mourenza, Álvaro, José A. Gil, Luis M. Mateos, and Michal Letek. 2021. "Novel Treatments and Preventative Strategies Against Food-Poisoning Caused by Staphylococcal Species" Pathogens 10, no. 2: 91. https://doi.org/10.3390/pathogens10020091

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop